Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Other Accumulated Expenses: 2021

  • Autolus Therapeutics' Other Accumulated Expenses was N/A to $1.4 million in Q4 2021 from the same period last year, while for Dec 2021 it was $1.4 million, marking a year-over-year change of. This contributed to the annual value of $1.5 million for FY2021, which is N/A change from last year.
  • Per Autolus Therapeutics' latest filing, its Other Accumulated Expenses stood at $1.4 million for Q4 2021.
  • Autolus Therapeutics' 5-year Other Accumulated Expenses high stood at $1.4 million for Q4 2021, and its period low was $1.4 million during Q4 2021.
  • In the last 1 years, Autolus Therapeutics' Other Accumulated Expenses had a median value of $1.4 million in 2021 and averaged $1.4 million.